comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists of semaglutide for patients type 2 diabetes in clinical practice A comparison of the effects

Obesity 31 , 111122 (2023)

In this analysis, the unadjusted comparison did not show a significant difference in all-cause mortality or recurrence-free survival between GLP-1 receptor agonists and SGLT2 inhibitors

However, as this analysis was conducted post hoc, the findings should be interpreted with caution and considered hypothesis-generating rather than evidence of superiority between agents

doi: 10.1038/s41591-022-01707-4 78 US National Institutes of Health

R., Obesity and Prognosis of Breast Cancer, Obesity Reviews 7 (2006): 333340

doi: 10.1016/j.diabres.2021.108904 [DOI] [PubMed] [Google Scholar] 87.Ma H, H LY, Z DL, et al